Rafael Melero
Overview
Explore the profile of Rafael Melero including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
56
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Blanco R, Aldasoro V, Maiz O, Melero R, Romero-Yuste S, De Miguel E, et al.
Rheumatology (Oxford)
. 2024 Dec;
PMID: 39658241
Objective: The spectrum of giant cell arteritis (GCA) includes different vascular phenotypes. Tocilizumab (TCZ) is the only biologic currently approved regardless these phenotypes. We aimed to assess the effectiveness of...
2.
Calderon-Goercke M, Loricera J, Moriano C, Castaneda S, Narvaez J, Aldasoro V, et al.
Clin Exp Rheumatol
. 2022 Nov;
41(4):829-836.
PMID: 36377586
Objectives: Tocilizumab (TCZ) is the only biologic therapy approved for giant cell arteritis (GCA). There is general agreement on the initial/maintenance dose, duration of TCZ therapy is not well established....
3.
Loricera J, Castaneda S, Moriano C, Narvaez J, Aldasoro V, Maiz O, et al.
Ther Adv Musculoskelet Dis
. 2022 Jul;
14:1759720X221113747.
PMID: 35898567
Background: Visual involvement is the most feared complication of giant cell arteritis (GCA). Information on the efficacy of tocilizumab (TCZ) for this complication is scarce and controversial. Objective: We assessed...
4.
Calderon-Goercke M, Castaneda S, Aldasoro V, Villa I, Moriano C, Romero-Yuste S, et al.
Semin Arthritis Rheum
. 2021 Feb;
51(2):387-394.
PMID: 33607384
Objective: To compare the efficacy and safety of TCZ in monotherapy (TCZ) vs. combined with conventional immunosuppressive drugs (TCZ) in Giant Cell Arteritis (GCA) in a clinical practice scenario. Methods:...
5.
Calderon-Goercke M, Castaneda S, Aldasoro V, Villa I, Prieto-Pena D, Atienza-Mateo B, et al.
Clin Exp Rheumatol
. 2020 May;
38 Suppl 124(2):112-119.
PMID: 32441643
Objectives: A potential point of concern among clinicians is whether results derived from the clinical trials can be reasonably applied or generalised to a definable group of patients seen in...
6.
Calderon-Goercke M, Loricera J, Aldasoro V, Castaneda S, Villa I, Humbria A, et al.
Semin Arthritis Rheum
. 2019 Jan;
49(1):126-135.
PMID: 30655091
Objective: Tocilizumab (TCZ) has shown efficacy in clinical trials on giant cell arteritis (GCA). Real-world data are scarce. Our objective was to assess efficacy and safety of TCZ in unselected...